Multihance
Active Ingredient(s): Gadobenate DimeglumineFDA Approved: * November 23, 2004
Pharm Company: * BRACCO
Category: Diagnostic Aid
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Multihance Overview
Gadobenic acid (INN, trade name MultiHance) is a complex of gadolinium with the ligand BOPTA. In the form of the methylglucamine salt meglumine gadobenate (INNm) or gadobenate dimeglumine (USAN), it is used as a gadolinium-based MRI contrast medium.[1] BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995.&...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gadobenic_acid
Recent Multihance Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Gadobenate Dimeglumine
- Injection: 10.58gm/20ml (529mg/ml), 2.645gm/5ml (529mg/ml), 26.45gm/50ml (529mg/ml), 5.29gm/10ml (529mg/ml), 52.9gm/100ml (529mg/ml), 7.935gm/15ml (529mg/ml)
NDC Database Records for Multihance: (2 results)
Sorted by National Drug Code- 0270-5164 Multihance 529 mg/ml Intravenous Injection, Solution by Bracco Diagnostics Inc
- 0270-5264 Multihance 529 mg/ml Intravenous Injection, Solution by Bracco Diagnostics Inc
Other drugs which contain Gadobenate Dimeglumine or a similar ingredient: (2 results)
- GADOBENATE DIMEGLUMINE
- MULTIHANCE MULTIPACK Gadobenate Dimeglumine